Definium Therapeutics
DFTX · Nasdaq · United States
Share price · DFTX
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when DFTX's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 6 Nov 2026+9.6%
Nothing announced by DFTX that day or the session before.
- 2 Nov 2026-10.6%
Nothing announced by DFTX that day or the session before.
- 24 Jun 2026+16.4%
- 22 Jun 2026+49.8%
- 15 Jun 2026-4.0%
- 21 May 2026+8.5%
- 8 May 2026-5.0%
- 27 Apr 2026-6.7%
Nothing announced by DFTX that day or the session before.
- 1 Apr 2026+9.0%
- 20 Jan 2026+11.5%
Share of unusual movement by asset
For each asset, the share of DFTX's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
Lysergide tartrate (LSD)(DT120) | Phase 3 | 5-HT2A receptorSmall molecule | Major Depressive DisorderAttention Deficit Hyperactivity DisorderGeneralized Anxiety Disorder |
Upcoming events
(1 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (1)
September 2027 (1)
What to watch
Regulatory and conference events
(3)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | — | $46M | $241M+ $806M short-term inv. | $51M-$53M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | — | $49M | $655M+ $429M short-term inv. | $159M-$53M operating cash flow | report ↗ |
| 2026-Q1 | — | $41M | $263M+ $111M short-term inv. | $77M-$43M operating cash flow | report ↗ |
| 2025-Q3 | — | $31M | $20M+ $189M short-term inv. | $67M-$30M operating cash flow | report ↗ |
| 2025-Q2 | — | $30M | $33M+ $150M short-term inv. | $43M-$30M operating cash flow | report ↗ |
| 2025-Q1 | — | $23M | $83M+ $130M short-term inv. | $23M-$29M operating cash flow | report ↗ |
| 2024-Q3 | — | $17M | $295M | $14M-$17M operating cash flow | report ↗ |
| 2024-Q2 | — | $15M | $243M | $5.8M-$20M operating cash flow | report ↗ |
| 2024-Q1 | — | $12M | $252M | $54M-$17M operating cash flow | report ↗ |
| 2023-Q3 | — | $13M | $118M | $18M-$17M operating cash flow | report ↗ |
| 2023-Q2 | — | $15M | $117M | $29M-$14M operating cash flow | report ↗ |
| 2023-Q1 | — | $13M | $129M | $25M-$13M operating cash flow | report ↗ |
| 2022-Q3 | — | $7.8M | $155M | $16M-$9.3M operating cash flow | report ↗ |
| 2022-Q2 | — | $9.3M | $106M | $17M-$15M operating cash flow | report ↗ |
| 2022-Q1 | — | $10M | $120M | $18M-$13M operating cash flow | report ↗ |
| 2021-Q3 | — | $9.0M | — | $17M-$17M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $118M | $258M+ $154M short-term inv. | $46M-$132M operating cash flow | report ↗ |
Definium Therapeutics reported full-year 2025 results with revenue not disclosed. R&D expense was $117.67M, up 80.2% YoY, and the company posted a net loss of $183.79M, with a quarterly net burn of $183.79M. Cash and equivalents stood at $257.84M, while total cash, cash equivalents, and investments were $411.6M as of December 31, 2025, compared to $273.7M in the prior year.
Management expects the $411.6M cash position to fund operations into 2028. Clinically, the Phase 3 MDD trial Emerge is fully enrolled with topline data anticipated in late 2Q 2026, the Phase 3 GAD trial Voyage is approximately 80% enrolled with topline data expected in early 3Q 2026, and the Phase 3 GAD trial Panorama remains on track for a 2H 2026 readout. Additional highlights include the completed ~$259M equity financing, publication of Phase 2b GAD results in JAMA, initiation of a Phase 2a study for DT402 in autism spectrum disorder, and a planned Investor and Analyst Day on April 22, 2026.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $65M | $274M+ $0 short-term inv. | $27M-$79M operating cash flow | report ↗ |
| 2023-FY | — | $52M | $100M | $24M-$64M operating cash flow | report ↗ |
| 2022-FY | — | $36M | $142M | $14M-$50M operating cash flow | report ↗ |
| 2021-FY | — | $35M | $134M | $23M-$46M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 17 sales ($7.0M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-25 | Roberts Brandi · Chief Financial Officer | Open-market sale | 3,377 | $36.57 | $123K | Form 4 |
| 2026-09-25 | Sullivan Mark · Chief Legal Officer | Open-market sale | 14,051 | $36.57 | $514K | Form 4 |
| 2026-09-25 | Wiley Matthew T. · Chief Commercial Officer | Open-market sale | 3,097 | $36.57 | $113K | Form 4 |
| 2026-09-25 | Barrow Robert · director, Chief Executive Officer | Open-market sale | 31,550 | $36.57 | $1.2M | Form 4 |
| 2026-09-25 | Karlin Daniel · director, Chief Medical Officer | Open-market sale | 10,853 | $36.57 | $397K | Form 4 |
| 2026-09-18 | Vallone Carol A · director | Option exercise | 1,086 | $35.52 | $39K | Form 4 |
| 2026-09-18 | Krebs Andreas · director | Option exercise | 1,629 | $35.52 | $58K | Form 4 |
| 2026-09-18 | Vallone Carol A · director | Option exercise (derivative) | 1,086 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 245 reporting institutions held 78.4M shares ($1.5B, 71.8% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 8,480,230 | $160.3M |
| 2 | Driehaus Capital Management LLC | 5,911,889 | $111.7M |
| 3 | Avoro Capital Advisors LLC | 5,000,000 | $94.5M |
| 4 | JANUS HENDERSON GROUP PLC | 3,556,041 | $67.2M |
| 5 | Deep Track Capital, LP | 3,000,000 | $56.7M |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 2,495,399 | $47.2M |
| 7 | STATE STREET CORP | 2,471,873 | $46.7M |
| 8 | Octagon Capital Advisors LP | 2,440,000 | $46.1M |
| 9 | Commodore Capital LP | 2,000,000 | $37.8M |
| 10 | FMR LLC | 1,809,610 | $34.2M |
| 11 | Trails Edge Capital Partners, LP | 1,738,110 | $32.9M |
| 12 | GOLDMAN SACHS GROUP INC | 1,675,411 | $31.7M |
| 13 | ArrowMark Colorado Holdings LLC | 1,594,717 | $30.1M |
| 14 | CITADEL ADVISORS LLC | 1,333,442 | $25.2M |
| 15 | WELLINGTON MANAGEMENT GROUP LLP | 1,304,749 | $24.7M |